IMMUTEP GRANTED EUROPEAN PATENT FOR EFTILAGIMOD ALPHA IN CANCER.
SYDNEY, AUSTRALIA – 22 August 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 2601962) entitled "LAG-3 dosage regime for use in the treatment of cancer” by the European Patent Office.
For further information please download the attached PDF:
Download this document
